Latest news
Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
FDA has approved belzutifan plus lenvatinib after PD-1 or PD-L1 therapy in advanced clear-cell renal cell carcinoma. The combination improved progression-free survival and response against cabozantinib. Overall survival did not cross the statistical line.
The Air We Breathe May Be Shaping the Future Burden of Blindness
Ozempic and Eye Health: Balancing Metabolic Benefits with Vision Risks
An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer
Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test
AI Pathology Starts Moving Toward Treatment Selection
Hepatitis B Functional Cure Moves Closer, But Access Still Starts With Diagnosis
Ebola PHEIC Turns Outbreak Control Into a Preparedness Test
Huntington’s Disease Gets an Oral Target-Engagement Signal
A Urine Test for Alzheimer’s Would Change the Access Conversation
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.